ZINZINO AB (PUBL): PRELIMINARY SALES REPORT APRIL 2020
Strong sales growth during April; Zinzino group revenue increased with a total of 53%, compared with the previous year.
The revenue in April for Zinzino's sales markets increased by 64% to MSEK 83.9. (51.3) primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 40% and amounted to MSEK 3.6 (6.0) due to high level of internal production. Overall, the Group increased revenues by 53% to MSEK 87.5 (57.3) compared with the previous year.
Accumulated revenue for January – April 2020 increased by 46% MSEK 329.6 (225.0).
Revenues distributed as follows:
|Regions,MSEK||20-apr||19-apr||Change||YTD 2020||YTD 2019||Change|
|Europe Other Markets||42.4||15.3||177%||456.4||60.6||142%|
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12, email@example.com
Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00,
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 13:00 the 5th of May 2020.
Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Adelaide. Zinzino is a public company and its shares are listed on Nasdaq First North Growth Market.